In a patient on daily oral HIV pre‑exposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine, how often should renal function be monitored?

Renal Function Monitoring in PrEP Patients

For patients on daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) PrEP, measure serum creatinine and calculate creatinine clearance at baseline, at 1 month after initiation, then every 3 months during the first year, and every 6 months thereafter if stable. 1

Initial Monitoring Protocol

• Baseline assessment must include serum creatinine measurement and estimated glomerular filtration rate (eGFR) calculation before initiating PrEP 1, 2
• First follow-up visit should occur within 30 days of PrEP initiation with repeat creatinine measurement 3
• This early assessment is critical because most renal function changes occur within the first 12 weeks of TDF exposure, with mean creatinine increases of 0.03 mg/dL (4.6%) and mean creatinine clearance decreases of 4.8 mL/min (3.0%) observed by week 12 4

Standard Ongoing Monitoring

• Every 3 months during the first year: Measure creatinine clearance alongside mandatory HIV testing and STI screening 1
• Every 6 months after the first year: Continue creatinine monitoring if renal function remains stable 5, 1
• PrEP prescriptions should not exceed 90 days without interval testing, which naturally aligns with quarterly monitoring 1

High-Risk Patients Requiring More Frequent Monitoring

Increase monitoring frequency to every 1-3 months for patients with any of the following risk factors 1, 6, 7:

• Age >50 years (3.79-fold increased risk of developing eGFR <70 mL/min/1.73 m²) 4
• Baseline eGFR <90 mL/min/1.73 m² (9.59-fold increased risk of further decline) 4
• Baseline creatinine clearance 60-90 mL/min 1
• Concurrent use of antihypertensive or diabetes medications 1
• Decompensated cirrhosis, poorly controlled hypertension, proteinuria, uncontrolled diabetes, or active glomerulonephritis 5
• Concomitant nephrotoxic drugs or solid organ transplantation 5

Critical Monitoring Thresholds

Closer monitoring is required if patients develop 5:

• Creatinine clearance <60 mL/min
• Serum phosphate levels <2 mg/dL
• Rapid decline in kidney function (eGFR drops >25% and decreases to <50 mL/min/1.73 m² from baseline) 7
• New onset or worsening proteinuria or albuminuria 7

Important Clinical Caveats

• TDF-based PrEP is contraindicated in patients with creatinine clearance <60 mL/min/1.73 m² 1, 2
• For patients with creatinine clearance 30-60 mL/min, switch to tenofovir alafenamide (TAF)-based PrEP (Descovy) rather than continuing TDF 8, 2
• Research demonstrates that renal function changes stabilize after 12 weeks and appear nonprogressive, with the difference between PrEP and placebo waning after 12 months 4, 9
• A real-world study found that 23% of participants showed eGFR reductions >10 mL/min/1.73 m² at week 4, suggesting early monitoring can identify those at risk 10
• The small declines in eGFR (average 1.23-1.59 mL/min/1.73 m² vs placebo) are not accompanied by substantial increases in clinically relevant (≥25%) eGFR decline 9

Alternative Formulation Monitoring

For patients on TAF-based PrEP (Descovy), monitoring requirements differ 8:

• Creatinine clearance at the first quarterly visit (3 months)
• Then annually thereafter (rather than every 6 months)
• This reflects TAF's superior renal safety profile compared to TDF 5, 8